Halozyme Therapeutics Inc
HALO67.350USD
+2.240+3.44%
Cierre 12/19, 16:00（ET）Cotizaciones retrasadas 15 min
7.92BCap. mercado
13.79P/E TTM
Más Datos de Halozyme Therapeutics Inc Compañía
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Información de Halozyme Therapeutics Inc
Símbolo de cotizaciónHALO
Nombre de la empresaHalozyme Therapeutics Inc
Fecha de salida a bolsaJan 30, 2003
Director ejecutivoTorley (Helen I)
Número de empleados350
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
Dirección12390 El Camino Real
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92130
Teléfono18587948889
Sitio Webhttps://www.halozyme.com/
Símbolo de cotizaciónHALO
Fecha de salida a bolsaJan 30, 2003
Director ejecutivoTorley (Helen I)
Ejecutivos de Halozyme Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
708.72K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
74.04K
+5.96%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
22.08K
-30.79%
Ms. Cortney Caudill
Ms. Cortney Caudill
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
7.67K
--
Dr. Mahesh Krishnan, M.D.
Dr. Mahesh Krishnan, M.D.
Independent Director
Independent Director
--
--
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Director
Director
--
--
Ms. Moni Miyashita
Ms. Moni Miyashita
Independent Director
Independent Director
--
--
Mr. Jeffrey W. (Jeff) Henderson
Mr. Jeffrey W. (Jeff) Henderson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark Snyder
Mr. Mark Snyder
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
708.72K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
74.04K
+5.96%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
22.08K
-30.79%
Ms. Cortney Caudill
Ms. Cortney Caudill
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
7.67K
--
Dr. Mahesh Krishnan, M.D.
Dr. Mahesh Krishnan, M.D.
Independent Director
Independent Director
--
--
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Director
Director
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Royalties
205.64M
63.13%
Sales of proprietary products
46.45M
14.26%
Event-based development and regulatory milestones and other fees
24.50M
7.52%
Sales of bulk rHuPH20
23.27M
7.14%
Sales of device partnered products
11.79M
3.62%
Otro
14.07M
4.32%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Royalties
205.64M
63.13%
Sales of proprietary products
46.45M
14.26%
Event-based development and regulatory milestones and other fees
24.50M
7.52%
Sales of bulk rHuPH20
23.27M
7.14%
Sales of device partnered products
11.79M
3.62%
Otro
14.07M
4.32%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.86%
BlackRock Institutional Trust Company, N.A.
9.68%
State Street Investment Management (US)
4.27%
Arrowstreet Capital, Limited Partnership
2.80%
UBS Financial Services, Inc.
2.49%
Otro
70.90%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.86%
BlackRock Institutional Trust Company, N.A.
9.68%
State Street Investment Management (US)
4.27%
Arrowstreet Capital, Limited Partnership
2.80%
UBS Financial Services, Inc.
2.49%
Otro
70.90%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
53.00%
Investment Advisor/Hedge Fund
35.16%
Hedge Fund
8.04%
Research Firm
4.70%
Pension Fund
2.37%
Bank and Trust
1.48%
Individual Investor
1.13%
Sovereign Wealth Fund
0.88%
Family Office
0.09%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
1096
120.60M
102.56%
-9.25M
2025Q2
1037
125.48M
107.21%
-10.05M
2025Q1
1043
127.91M
103.79%
-10.64M
2024Q4
999
127.73M
103.64%
-14.45M
2024Q3
953
129.39M
102.16%
-10.33M
2024Q2
905
126.24M
99.18%
-14.91M
2024Q1
870
127.71M
100.45%
-13.70M
2023Q4
850
128.82M
97.51%
-11.71M
2023Q3
836
127.73M
96.80%
-13.97M
2023Q2
838
128.24M
97.33%
-12.36M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
12.22M
10.45%
-584.32K
-4.56%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.71M
10.01%
-3.28M
-21.88%
Jun 30, 2025
State Street Investment Management (US)
5.94M
5.07%
-117.96K
-1.95%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
2.54M
2.17%
+1.43M
+127.81%
Jun 30, 2025
UBS Financial Services, Inc.
1.42M
1.21%
+1.12M
+370.46%
Jun 30, 2025
Snyder Capital Management, L.P.
3.40M
2.9%
-276.61K
-7.53%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.43M
2.08%
-736.73K
-23.25%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.01M
1.72%
-14.43K
-0.71%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Future Fund Long/Short ETF
4.62%
First Trust NYSE Arca Biotechnology Index Fund
3.42%
Congress SMid Growth ETF
2.79%
Invesco Biotechnology & Genome ETF
2.61%
Invesco S&P MidCap 400 GARP ETF
2.23%
Janus Henderson Small/Mid Cap Growth Alpha ETF
2.18%
Virtus LifeSci Biotech Products ETF
1.91%
Alpha Architect US Quantitative Value ETF
1.74%
State Street SPDR S&P Biotech ETF
1.69%
First Trust Health Care Alphadex Fund
1.55%
Ver más
Future Fund Long/Short ETF
Proporción4.62%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.42%
Congress SMid Growth ETF
Proporción2.79%
Invesco Biotechnology & Genome ETF
Proporción2.61%
Invesco S&P MidCap 400 GARP ETF
Proporción2.23%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proporción2.18%
Virtus LifeSci Biotech Products ETF
Proporción1.91%
Alpha Architect US Quantitative Value ETF
Proporción1.74%
State Street SPDR S&P Biotech ETF
Proporción1.69%
First Trust Health Care Alphadex Fund
Proporción1.55%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Halozyme Therapeutics Inc?
Los cinco principales accionistas de Halozyme Therapeutics Inc son:
The Vanguard Group, Inc. posee 12.22M acciones, lo que representa el 10.45% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 11.71M acciones, lo que representa el 10.01% del total de acciones.
State Street Investment Management (US) posee 5.94M acciones, lo que representa el 5.07% del total de acciones.
Arrowstreet Capital, Limited Partnership posee 2.54M acciones, lo que representa el 2.17% del total de acciones.
UBS Financial Services, Inc. posee 1.42M acciones, lo que representa el 1.21% del total de acciones.
The Vanguard Group, Inc. posee 12.22M acciones, lo que representa el 10.45% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 11.71M acciones, lo que representa el 10.01% del total de acciones.
State Street Investment Management (US) posee 5.94M acciones, lo que representa el 5.07% del total de acciones.
Arrowstreet Capital, Limited Partnership posee 2.54M acciones, lo que representa el 2.17% del total de acciones.
UBS Financial Services, Inc. posee 1.42M acciones, lo que representa el 1.21% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Halozyme Therapeutics Inc?
Los tres principales tipos de accionista de Halozyme Therapeutics Inc son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
¿Cuántas instituciones poseen acciones de Halozyme Therapeutics Inc (HALO)?
A fecha de 2025Q3, 1096 instituciones poseen acciones de Halozyme Therapeutics Inc, con un valor de mercado combinado de aproximadamente 120.60M, lo que representa el 102.56% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -4.66%.
¿Cuál es la mayor fuente de ganancias de Halozyme Therapeutics Inc?
El FY2025Q2, el segmento empresarial Royalties generó la ganancia más alta para Halozyme Therapeutics Inc, ascendiendo a 205.64M y representando el 63.13% de la ganancia total.
